Subsequently, based on the results of two clinical trials, FLAURA (NCT02296125) and ADAURA (NCT02511106), the U.S. FDA broadened the indications of osimertinib as the first‐line treatment for advanced NSCLC patients with sensitizing EGFR mutations or as an adjuvant therapy when surgery patients with sensitizing EGFR mutations.61, 62. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.